TOKYO – Even considering that much of the industry deals with life and death matters by the nature of the field, stem cells have long been a high drama part of biotechnology. And 2014 was no exception to that rule. Read More
Although it turned out to be a challenging month for biotech companies, it didn't take the gloss off what was a very positive year for the sector. In fact, many of the industry's blue chip, growth and emerging public biotech companies returned stunning percentage gains in their share values. Read More
